Mettler-Toledo International Inc. — Q2 2022 Form 10-Q
Reporting period: Three and six months ended June 30, 2022. Unaudited U.S. GAAP results. The company supplies precision instruments and related services for laboratory, industrial, retail, and other markets. Amounts below are in U.S. dollars; financial statement amounts are converted from thousands to millions.
Financial results
| Metric | Q2 2022 | Q2 2021 | First half 2022 | First half 2021 |
|---|---|---|---|---|
| Net sales | $978.4m | $924.4m | $1,876.2m | $1,728.7m |
| Gross profit | $571.7m | $536.9m | $1,091.2m | $1,008.6m |
| Gross margin | 58.4% | 58.1% | 58.2% | 58.3% |
| Earnings before taxes | $256.7m | $230.4m | $469.7m | $415.8m |
| Net earnings | $212.1m | $184.8m | $386.1m | $334.4m |
| Diluted EPS | $9.29 | $7.85 | $16.84 | $14.17 |
| Operating cash flow | Not separately stated | Not separately stated | $310.0m | $404.4m |
- Q2 sales increased 6% in reported dollars and 10% in local currencies; first-half sales increased 9% and 12%, respectively. First-half growth included about 1% from the PendoTECH acquisition.
- Q2 net earnings rose about 15% year over year; first-half net earnings rose about 15%. Diluted EPS increased about 18% for Q2 and about 19% for the first half.
- Q2 gross margin improved 0.3 percentage points, reflecting favorable pricing and higher volume, partly offset by material costs. First-half gross margin declined 0.1 point as material and transportation costs increased.
- Q2 earnings before taxes were 26.2% of sales, versus 24.9% a year earlier; first-half figures were 25.0% versus 24.0%. SG&A as a share of sales fell in both periods. Interest expense increased to $12.8m in Q2 and $24.1m in the first half.
Cash, debt, and liquidity
- At June 30, 2022, cash was $109.4m, total debt was $1,928.0m, including $106.6m current debt, and long-term debt was $1,821.5m. Approximate debt net of cash was $1.82bn.
- The company had $528.0m available under its credit agreement and reported compliance with debt covenants. It stated that cash, operating cash flow, and available borrowing capacity should cover anticipated needs for the foreseeable future.
- First-half operating cash flow declined $94.4m to $310.0m. Management attributed the decrease primarily to higher cash incentive payments and increased inventory. Inventory rose to $463.3m from $414.5m at year-end.
- First-half capital expenditures were $62.4m, compared with $47.4m. The company received $25.0m of the $35.8m total government funding expected through 2023 for domestic pipette-tip capacity and automation.
- First-half share repurchases totaled $550.0m, versus $475.0m a year earlier. Remaining program authorization was $1.5bn. Shareholders’ equity was $7.3m at June 30, down from $171.4m at year-end, with treasury stock of $6.79bn; the large repurchase balance is an important capital-allocation consideration.
Business trends and material changes
- Growth was broad-based, with strong customer demand reported across most businesses and regions. Laboratory sales rose 8% in Q2 and 11% in the first half in reported dollars; industrial sales rose 4% and 7%. Retail sales fell 4% in Q2 and 11% in the first half in reported dollars.
- In Q2, reported external-customer sales increased 12% in U.S. Operations, 3% in Swiss Operations, and 12% in Chinese Operations; Western Europe declined 6%. In local currencies, Western European external sales grew 7%, indicating a substantial reported-currency headwind.
- China external sales grew 12% in Q2 and 14% in the first half in reported dollars, with particular strength in laboratory and core industrial products. Food retailing was weak, especially in China.
- Segment profit for the first half increased to $526.7m from $465.9m. U.S., Swiss, Chinese, and Other segment profit increased; Western Europe declined, primarily due to currency translation and higher material and transportation costs.
- Comprehensive income was $180.6m in Q2, below net earnings of $212.1m, mainly reflecting other comprehensive losses. First-half comprehensive income was $358.9m versus $366.8m a year earlier, despite higher net earnings.
Outlook, risks, and other notable items
- The filing provides no specific full-year revenue, earnings, or EPS guidance. Management noted results for the interim periods are not necessarily indicative of full-year results.
- Management cited ongoing supply-chain disruption, component and material shortages, supplier and transportation delays, and inflationary cost increases. These could affect deliveries, sales, and profitability.
- COVID-19 and potential renewed lockdowns, particularly in China, remain uncertain risks to manufacturing, supply chains, and demand. Facilities were operating, with some delivery interruptions reported.
- The company suspended shipments to Russia after the February 2022 invasion of Ukraine. Russia and Ukraine represented approximately 1% of 2021 sales combined; management reported immaterial assets and liabilities there and no manufacturing in either country. The conflict may add inflation, energy, and transportation pressures.
- Foreign exchange is material: management estimated that a 1% strengthening of the Swiss franc against the euro could reduce annual pretax earnings by approximately $1.9m–$2.1m; a 1% weakening of the Chinese renminbi against the U.S. dollar could reduce them by approximately $3.3m–$3.5m. A 5% weakening of the dollar against debt currencies could raise reported debt by about $35m.
- Restructuring charges were $5.8m in the first half, versus $2.1m; they were primarily employee-related. Derivative-related foreign-exchange losses on short-term intercompany balances were partly offset by underlying transaction gains or losses.
- The company paid $10.0m of PendoTECH contingent consideration in Q2 and reported a remaining estimated obligation of $10.0m. It reported no legal proceedings expected to have a material adverse effect.
Investor verification points
- Assess whether growth and pricing can offset material, freight, and other inflationary costs, and whether gross-margin performance is improving or deteriorating.
- Track cash conversion, inventory growth, and the drivers of the year-over-year decline in operating cash flow.
- Review debt maturities, interest-rate exposure, foreign-currency effects, and the planned September 2022 issuance of the remaining $150m of 15-year notes.
- Evaluate the scale and funding of share repurchases relative to cash generation, debt, and the very low reported shareholders’ equity.
- Monitor China lockdown and supply-chain developments, retail weakness, currency translation, and the remaining PendoTECH contingent consideration.